1227417-79-9

Upstream product

• 638-07-3 ethyl (2-chloroaceto)acetate 
• 4922-98-9 3-phenyl-1H-1,2,4-triazol-5-amine 
• 98-88-4 benzoyl chloride 
• 3679-92-3 N-(benzamido)-guanidine 

Downstream Products

• 1227417-78-8 C₂₁H₂₄N₄O₄ 
• 1227416-15-0 C₂₂H₁₉ClN₄O₂ 
• 1227416-14-9 C₂₂H₁₉ClN₄O₂ 
• 1227418-34-9 C₁₉H₁₃ClN₄O₃ 
• 1227415-32-8 C₂₁H₂₁N₅O 
• 1227413-92-4 C₁₉H₁₅ClN₄O₂ 
• 1227416-17-2 C₁₉H₁₂ClN₅O₂ 
• 1227415-60-2 C₁₉H₁₅ClN₄OS 
• 1227415-55-5 C₂₀H₁₈N₄OS 
• 1227416-20-7 C₂₁H₁₇ClN₄O₄ 
• 1227415-61-3 C₂₂H₂₀ClN₅O 
• 1227415-63-5 C₂₂H₂₀ClN₅O 
• 1227415-64-6 C₂₃H₂₄N₆O 
• 1227415-65-7 C₂₁H₁₇ClN₄O₂ 

Relevant academic research and scientific papers

Triazolopyrimidine derivative compounds

PROBLEM TO BE SOLVED: To provide a FABP4 probe having low lipid solubility and capable of specifically binding to FABP4.SOLUTION: This invention relates to a triazolopyrimidine derivative compound comprising a fluorine atom or salt thereof, and a pharmaceutical composition comprising the same.

INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP)

The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein ("FABP") inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the present invention is shown below: (I)